Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) CEO Ryan H. Saadi sold 1,438,206 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $1.23, for a total value of $1,768,993.38. Following the transaction, the chief executive officer now directly owns 116,814,453 shares of the company's stock, valued at approximately $143,681,777.19. This represents a 1.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Tevogen Bio Price Performance
Shares of Tevogen Bio stock traded down $0.07 on Thursday, hitting $1.27. The company's stock had a trading volume of 586,287 shares, compared to its average volume of 5,049,989. The firm has a fifty day moving average price of $1.13 and a 200-day moving average price of $1.20. Tevogen Bio Holdings Inc. has a 52-week low of $0.26 and a 52-week high of $3.09.
Analyst Upgrades and Downgrades
Separately, D. Boral Capital reiterated a "buy" rating and issued a $10.00 price target on shares of Tevogen Bio in a research report on Tuesday.
View Our Latest Report on TVGN
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in Tevogen Bio by 31.2% during the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock worth $465,000 after buying an additional 107,566 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock valued at $122,000 after acquiring an additional 13,595 shares during the last quarter. Nuveen LLC purchased a new stake in Tevogen Bio during the 1st quarter worth about $97,000. XTX Topco Ltd purchased a new stake in Tevogen Bio during the 4th quarter worth about $55,000. Finally, Barclays PLC raised its stake in Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after purchasing an additional 12,847 shares during the last quarter.
Tevogen Bio Company Profile
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Read More
Before you consider Semper Paratus Acquisition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Semper Paratus Acquisition wasn't on the list.
While Semper Paratus Acquisition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
